Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway

Oncotarget

Volumn 7, Issue 37, 2016, Pages 60712-60722

  Massihnia, Daniela ^a   Galvano, Antonio ^a   Fanale, Daniele ^a   Perez, Alessandro ^a   Castiglia, Marta ^a   Incorvaia, Lorena ^a   Listì, Angela ^a   Rizzo, Sergio ^a   Cicero, Giuseppe ^a   Bazan, Viviana ^a   Castorina, Sergio ^b,c   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Fondazione Mediterranea GB Morgagni   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

ER; HER2; PI3K AKT mTOR inhibitor; Target therapy; Triple negative breast cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALPELISIB; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; BUPARLISIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DACTOLISIB; DOXORUBICIN; ERIBULIN; EVEROLIMUS; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATINUM DERIVATIVE; PROTEIN KINASE B; RAPAMYCIN; RUCAPARIB; SELUMETINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; VISTUSERTIB; ANTINEOPLASTIC AGENT; ONCOPROTEIN; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; DRUG TARGETING; HUMAN; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; ADULT; AGE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; FEMALE; METABOLISM; MIDDLE AGED;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; FEMALE; HUMANS; MIDDLE AGED; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84991384840     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10858     Document Type: Review

References (107)

1. Fanale D, Amodeo V, Corsini LR, Rizzo S, Bazan V and Russo A. Breast cancer genome-wide association studies: there is strength in numbers. Oncogene. 2012; 31(17):2121-2128
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-752
3. Fanale D, Bazan V, Corsini LR, Caruso S, Insalaco L, Castiglia M, Cicero G, Bronte G and Russo A. HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. Breast Cancer Res Treat. 2013; 140(3):505-517
4. Fanale D, Bazan V, Caruso S, Castiglia M, Bronte G, Rolfo C, Cicero G and Russo A. Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines. Biomed Res Int. 2013; 2013:746858
5. Sorlie T. The Impact of Gene Expression Patterns in Breast Cancer. Clin Chem. 2016
6. Purrington KS, Visscher DW, Wang C, Yannoukakos D, Hamann U, Nevanlinna H, Cox A, Giles GG, Eckel-Passow JE, Lakis S, Kotoula V, Fountzilas G, Kabisch M, Rudiger T, Heikkila P, Blomqvist C, et al. Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. Breast Cancer Res Treat. 2016
7. Mancini P, Angeloni A, Risi E, Orsi E and Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel). 2014; 6(4):2187-2223
8. Schnitt SJ. Will molecular classification replace traditional breast pathology? Int J Surg Pathol. 2010; 18(3 Suppl):162S-166S
9. Correa Geyer F and Reis-Filho JS. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Pathol. 2009; 17(4):285-302
10. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B and Senn HJ. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533-1546
11. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH and Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30(8):777-782
12. Zaharia M and Gomez H. [Triple negative breast cancer: a difficult disease to diagnose and treat]. Rev Peru Med Exp Salud Publica. 2013; 30(4):649-656
13. Schmadeka R, Harmon BE and Singh M. Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol. 2014; 141(4):462-477
14. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-2334
15. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K and Mitchell EP. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110(4):876-884
16. Tobin NP, Harrell JC, Lovrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Ferno M, Perou CM, Bergh J, Hatschek T and Lindstrom LS. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol. 2015; 26(1):81-88
17. Russo A, Calò V, Bruno L, Schirò V, Agnese V, Cascio S, Foddai E, Fanale D, Rizzo S, Di Gaudio F, Gulotta E, Surmacz E, Di Fede G and Bazan V. Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? Breast Cancer Research and Treatment. 2008; 113(1):67-70
18. Anders CK and Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009; 9 Suppl 2:S73-81
19. Cadoo KA, Fornier MN and Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging. 2013; 57(4):312-321
20. Nowacka-Zawisza M and Krajewska WM. [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches]. Postepy Hig Med Dosw (Online). 2013; 67:1090-1097
21. Guarneri V, Dieci MV and Conte P. Relapsed triplenegative breast cancer: challenges and treatment strategies. Drugs. 2013; 73(12):1257-1265
22. Ueng SH, Chen SC, Chang YS, Hsueh S, Lin YC, Chien HP, Lo YF, Shen SC and Hsueh C. Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. Int J Clin Exp Pathol. 2012; 5(8):806-813
23. Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls EB, Lausen K, Hanker L, Holtrich U, Becker S and Karn T. The prognostic impact of age in different molecular subtypes of breast cancer. Breast Cancer Res Treat. 2015; 152(3):667-673
24. Cinkaya A, Akin M and Sengul A. Evaluation of treatment outcomes of triple-negative breast cancer. J Cancer Res Ther. 2016; 12(1):150-154
25. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013; 12(1):104-116
26. Chacon RD and Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 2010; 12 Suppl 2:S3
27. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009; 27(27):4536-4541
28. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-2767
29. Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res. 2010; 16(2):681-690
30. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L and Swanton C. Assessment of an RNA interference screenderived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol. 2010; 11(4):358-365
31. Fanale D, Bronte G, Passiglia F, Calo V, Castiglia M, Di Piazza F, Barraco N, Cangemi A, Catarella MT, Insalaco L, Listi A, Maragliano R, Massihnia D, Perez A, Toia F, Cicero G, et al. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol (Amst). 2015; 2015:690916
32. Ishikawa T, Narui K, Tanabe M, Kida K, Oba MS, Yamada A, Ichikawa Y and Endo I. BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane. Eur J Surg Oncol. 2016
33. Hayes MJ, Thomas D, Emmons A, Giordano TJ and Kleer CG. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res. 2008; 14(13):4038-4044
34. McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T and Sasano H. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol. 2013; 133:66-76
35. Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A and Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer. 2015; 6(5-6):206-213
36. Rampurwala M, Wisinski KB and O'Regan R. Role of the androgen receptor in triple-negative breast cancer. Clin Adv Hematol Oncol. 2016; 14(3):186-193
37. Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM and Richer JK. Multiple molecular subtypes of triplenegative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015; 14(3):769-778
38. Cuenca-Lopez MD, Montero JC, Morales JC, Prat A, Pandiella A and Ocana A. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer. 2014; 14:302
39. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012; 486(7403):395-399
40. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011; 24(2):157-167
41. Crown J, O'Shaughnessy J and Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol. 2012; 23 Suppl 6:vi56-65
42. Berrada N, Delaloge S and Andre F. Treatment of triplenegative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol. 2010; 21 Suppl 7:vii30-35
43. Fornier M and Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J. 2012; 18(1):41-51
44. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF and Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013; 19(19):5533-5540
45. Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V and Barni S. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014; 144(2):223-232
46. Wahba HA and El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015; 12(2):106-116
47. Telli ML and Ford JM. Novel treatment approaches for triple-negative breast cancer. Clin Breast Cancer. 2010; 10 Suppl 1:E16-22
48. Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M and Sinha N. Therapeutic targets of triple-negative breast cancer: a review. Br J Pharmacol. 2015; 172(17):4228-4237
49. Yi YW, Kang HJ, Bae EJ, Oh S, Seong YS and Bae I. beta-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells. Exp Mol Med. 2015; 47:e143
50. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D and Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol. 2012; 23(9):2223-2234
51. Massihnia D, Perez A, Bazan V, Bronte G, Castiglia M, Fanale D, Barraco N, Cangemi A, Di Piazza F, Calo V, Rizzo S, Cicero G, Pantuso G and Russo A. A headlight on liquid biopsies: a challenging tool for breast cancer management. Tumour Biol. 2016
52. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318(5853):1108-1113
53. Fanale D, Amodeo V, Bazan V, Insalaco L, Incorvaia L, Barraco N, Castiglia M, Rizzo S, Santini D, Giordano A, Castorina S and Russo A. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer? Oncotarget. 2016; doi: 10.18632/oncotarget.8722
54. Gonzalez-Angulo AM and Blumenschein GR, Jr. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev. 2013; 39(4):313-320
55. Mayer IA and Arteaga CL. The PI3K/AKT Pathway as a Target for Cancer Treatment. Annu Rev Med. 2016; 67:11-28
56. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist. 2011; 16 Suppl 1:12-19
57. Cangemi A, Fanale D, Rinaldi G, Bazan V, Galvano A, Perez A, Barraco N, Massihnia D, Castiglia M, Vieni S, Bronte G, Mirisola M and Russo A. Dietary restriction: could it be considered as speed bump on tumor progression road? Tumour Biol. 2016
58. Guo S, Liu M and Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta. 2011; 1815(2):197-213
59. Zhao L and Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008; 27(41):5486-5496
60. Lauring J, Park BH and Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw. 2013; 11(6):670-678
61. Ogawa A, Firth AL, Yao W, Madani MM, Kerr KM, Auger WR, Jamieson SW, Thistlethwaite PA and Yuan JX. Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009; 297(4):L666-676
62. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M and Dorigo O. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res. 2011; 17(8):2373-2384
63. Salmena L, Carracedo A and Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008; 133(3):403-414
64. Agoulnik IU, Hodgson MC, Bowden WA and Ittmann MM. INPP4B: the new kid on the PI3K block. Oncotarget. 2011; 2(4):321-328. doi: 10.18632/oncotarget.260
65. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70
66. Dowling RJ, Topisirovic I, Fonseca BD and Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010; 1804(3):433-439
67. Zoncu R, Efeyan A and Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011; 12(1):21-35
68. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ and Holz MK. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem. 2009; 284(10):6361-6369
69. Khotskaya YB, Goverdhan A, Shen J, Ponz-Sarvise M, Chang SS, Hsu MC, Wei Y, Xia W, Yu D and Hung MC. S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. Am J Transl Res. 2014; 6(4):361-376
70. Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR and Arteaga CL. Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Res. 2016; 76(2):440-452
71. Montero JC, Esparis-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocana A and Pandiella A. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene. 2014; 33(2):148-156
72. Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A and Duffy MJ. mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. Breast. 2012; 21(2):178-182
73. Pelicano H, Zhang W, Liu J, Hammoudi N, Dai J, Xu RH, Pusztai L and Huang P. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Res. 2014; 16(5):434
74. Paplomata E and O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014; 6(4):154-166
75. Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K, Yoshida T, Fujiwara Y and Tamura K. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci. 2012; 103(9):1665-1671
76. Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L and Tomao S. Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther. 2015; 8:177-193
77. Mayer IA, Jovanovic B, Abramson VG, Mayer EL, Sanders ME, Bardia A, Dillon PM, Kuba MG, Carpenter JT, Chang JC, Lehmann BD, Meszoely IM, Grau A, Shyr Y, Arteaga CL, Chen X, et al. Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC). Cancer Research. 2014; 73(24 Supplement):PD1-6-PD1-6
78. Jerusalem G, Rorive A and Collignon J. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer (Dove Med Press). 2014; 6:43-57
79. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancerdagger. Ann Oncol. 2014; 25(6):1122-1127
80. Singh J, Novik Y, Stein S, Volm M, Meyers M, Smith J, Omene C, Speyer J, Schneider R, Jhaveri K, Formenti S, Kyriakou V, Joseph B, Goldberg JD, Li X, Adams S, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res. 2014; 16(2):R32
81. Schmidt G, Gerlinger C, Juhasz-Boss I, Stickeler E, Rody A, Liedtke C, Wimberger P, Link T, Muller E, Fehm T, Abel M, Stein S, Bohle R, Endrikat J and Solomayer EF. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 2016
82. Reis-Filho JS and Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008; 52(1):108-118
83. Simon N, Antignani A, Sarnovsky R, Hewitt SM and FitzGerald D. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer. J Natl Cancer Inst. 2016; 108(8)
84. Passiglia F, Bronte G, Castiglia M, Listi A, Calo V, Toia F, Cicero G, Fanale D, Rizzo S, Bazan V and Russo A. Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls? Expert Opin Biol Ther. 2015; 15(11):1553-1566
85. Gogineni K and DeMichele A. Current approaches to the management of Her2-negative metastatic breast cancer. Breast Cancer Res. 2012; 14(2):205
86. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H and Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005; 65(16):7052-7058
87. Hahn OM, Ma CX, Lin L, Hou D, Sattar H, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Watson MA, Ellis M, Conzen SD and Fleming GF. A phase II trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer. Cancer Research. 2014; 69(2 Supplement):407
88. Wan X, Zheng X, Pang X, Pang Z, Zhao J, Zhang Z, Jiang T, Xu W, Zhang Q and Jiang X. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain. Oncotarget. 2016; doi: 10.18632/oncotarget.8697
89. Liu T, Yacoub R, Taliaferro-Smith LD, Sun SY, Graham TR, Dolan R, Lobo C, Tighiouart M, Yang L, Adams A and O'Regan RM. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Mol Cancer Ther. 2011; 10(8):1460-1469
90. Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH, Larijani B, et al. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res. 2014; 16(2):R36
91. Guo S, Liu M, Wang G, Torroella-Kouri M and Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta. 2012; 1825(2):207-222
92. Madden JM, Mueller KL, Bollig-Fischer A, Stemmer P, Mattingly RR and Boerner JL. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer. Breast Cancer Res Treat. 2014; 147(2):283-293
93. Vicier C, Dieci MV, Arnedos M, Delaloge S, Viens P and Andre F. Clinical development of mTOR inhibitors in breast cancer. Breast Cancer Res. 2014; 16(1):203
94. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M and Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015; 26(7):1346-1352
95. Fouque A, Jean M, van de Weghe P and Legembre P. Review of PI3K/mTOR inhibitors entering clinical trials to treat triple negative breast cancers. Recent Pat Anticancer Drug Discov. 2016
96. Kalinsky K, Sparano JA, Andreopoulou E, Taback B, Wlechmann LS, Feldman SM, Ananthakrishnan P, Hibshoosh H, Manavaian J, Crew KD, Maurer MA and Hershman DL. Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. Journal of Clinical Oncology. 2014; 32(15)
97. Hosford SR and Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med. 2014; 7:203-215
98. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M and Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):235-244
99. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH and de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-134
100. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-921
101. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC and Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16):8109-8115
102. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, Huntsman D, Carmichael J, Macpherson E and Oza AM. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triplenegative breast cancer. Journal of Clinical Oncology. 2010; 28(15)
103. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzman M, Grueso J, Rodriguez O, Calvo MT, Aura C, Diez O, Rubio IT, Perez J, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012; 2(11):1036-1047
104. Ayub A, Yip WK and Seow HF. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line. Biomed Pharmacother. 2015; 75:40-50
105. Kimbung S, Biskup E, Johansson I, Aaltonen K, Ottosson-Wadlund A, Gruvberger-Saal S, Cunliffe H, Fadeel B, Loman N, Berglund P and Hedenfalk I. Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Lett. 2012; 319(2):232-241
106. Toss A and Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res. 2015; 17:60
107. Carey L, Winer E, Viale G, Cameron D and Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010; 7(12):683-692